Related Experiment Video
Updated: Jun 27, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice
David M Taylor1, Catrin Fischetti, Anna Sparshatt
1Pharmacy Department, Maudsley Hospital, London, UK. david.taylor@slam.nhs.uk
Objective:
To evaluate outcomes of clinical use of risperidone long-acting injection (RLAI) and determine factors predicting continuation with treatment.
Method:
This prospective, 3-year follow-up of consecutive patients started on treatment with RLAI in normal clinical practice between August 2002 and September 2003 obtained demographic and clinical data from case notes, prescription charts, and hospital computer records. To determine predictors of continuation, a proportional hazards regression (Cox) model was constructed.
Results:
The study included 211 evaluable patients. Over 3 years, 84% of subjects discontinued RLAI; 27.7% of these switched to oral risperidone. The Cox model showed that younger age (p = .001), longer duration of illness (p = .001), inpatient status at initiation (p = .002), and an RLAI dose of 25 mg/2 weeks (p < .001) predicted greater probability of discontinuation.
Conclusion:
A small proportion of patients initiated on treatment with RLAI continued for 3 years. Outcome is likely to be improved by targeting RLAI treatment at specific patient groups and by using a dose of more than 25 mg/2 weeks.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Psychosis: Goals of Pharmacotherapy
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug Therapy
Antianxiety Medications
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
